

## VAC\_03 - An alphavirus-derived replicon polyvalent RNA vaccine induces neutralizing antibodies in mice against omicron SARS-CoV-2 variant of concern

Vinicius Pinto Costa Rocha<sup>3</sup>; Breno Cardim Barreto<sup>1</sup>; Katharine Valéria Saraiva Hodel<sup>3</sup>; Larissa Moraes dos Santos Fonseca<sup>3</sup>; Jesse Erasmus<sup>2</sup>; Amit Khandhar<sup>2</sup>; Steve Reed<sup>2</sup>; Roberto José da Silva Badaró<sup>3</sup>; Milena Botelho Pereira Soares<sup>3</sup>; Bruna Aparecida de Souza Machado<sup>3</sup>.

<sup>1</sup>Gonçalo Moniz Institute/Fiocruz-Bahia

<sup>2</sup>HDT Biocorp

<sup>3</sup>Serviço Nacional de Aprendizagem Industrial/SENAI CIMATEC

**Introduction:** Vaccination is the most effective approach to control the COVID-19. However, the literature has shown that neutralization of omicron is impaired by prophylaxis with wild type spike RNA vaccines.

**Objectives:** Our aim was to evaluate the efficacy of a polyvalent alphavirus-derived replicon (Rep) RNA vaccine to induce neutralizing antibodies (nAB) against omicron (B.1.159) pseudoviruses after D614G Rep-RNA pre-vaccination in mice. RepRNA encoding D614G and the spikes from VoCs alpha, beta, gamma, and omicron were produced by *in vitro* transcription and formulated with a cationic nanocarrier (LION™).

**Methodology:** Balb/c mice were previously immunized with two doses of 1µg LION/RepRNA-D614G 28 days apart, followed by vaccination with two doses of 1µg LION/RepRNA-omicron or polyvalent (0,2µg of each RepRNA-VoCs). The nAB was determined by pseudovirus neutralization assay, using phenotypic high content analysis with the percentage of ZsGreen positive cells as the readout. The plasma neutralization potency (pNT<sub>50</sub>) was calculated by non-linear regression from a plasma dilution curve from 1:40 to 1:2560.

**Results:** Pre-vaccinated mice were able to neutralize D614G pseudoviruses regardless of the vaccination with LION/RepRNA-omicron or polyvalent. Pre-vaccinated animals which received LION/RepRNA polyvalent presented the highest pNT<sub>50</sub> (3324), significantly more potent than mice that received LION/RepRNA-omicron pNT<sub>50</sub> (1210). Animals only vaccinated with LION/RepRNA-polyvalent neutralized better D614G pseudoviruses than mice immunized only with LION/RepRNA-omicron. The pre-vaccination with LION/RepRNA-D614G impaired the neutralizing capability of omicron pseudoviruses in animals vaccinated with LION/RepRNA-omicron. This phenotype was reverted using LION/RepRNA polyvalent (pNT<sub>50</sub> equal to 36 and 277, respectively). Two doses only of either LION/RepRNA-omicron or polyvalent induced more neutralizing antibodies than in pre-vaccinated mice which received LION/RepRNA-omicron (pNT<sub>50</sub> equal to 442 and 415, respectively).

**Conclusion:** Our results confirmed the previously reported data and showed the use of a LION/RepRNA-polyvalent vaccine can revert the phenotype. A polyvalent LION/RepRNA including the main VoCs can overcome the problem of neutralization escape.

**Keywords:** Covid-19, polyvalent vaccine, RNA